Your session is about to expire
← Back to Search
Hsp90 Inhibitor
Gamitrinib for Lymphoma
Phase 1
Waitlist Available
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests the safety of gamitrinib, a new drug for advanced cancer patients. Gamitrinib works by blocking a protein that helps cancer cells survive. The study aims to find the best dose and see how well it works.
Eligible Conditions
- Solid Tumors
- Lymphoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Determine the MTD and/or RP2D of gamitrinib when administered once weekly.
Secondary study objectives
Assess the pharmacodynamic effects of gamitrinib
Document any anti-tumor activity of single agent gamitrinib
Evaluate the overall safety profile of intravenously administered single-agent gamitrinib
+5 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
7Treatment groups
Experimental Treatment
Group I: Dose 6Experimental Treatment1 Intervention
Accelerated Phase: 320 mg Standard Phase: 85 mg
Group II: Dose 5Experimental Treatment1 Intervention
Accelerated Phase: 160 mg Standard Phase: 65 mg
Group III: Dose 4Experimental Treatment1 Intervention
Accelerated Phase: 80 mg Standard Phase: 50 mg
Group IV: Dose 3Experimental Treatment1 Intervention
Accelerated Phase: 40 mg Standard Phase: 35 mg
Group V: Dose 2Experimental Treatment1 Intervention
Accelerated Phase: 20 mg Standard Phase: 20 mg
Group VI: Dose 1Experimental Treatment1 Intervention
Accelerated Phase: 10 mg Standard Phase: 10 mg
Group VII: Dose -1Experimental Treatment1 Intervention
Accelerated Phase: - Standard Phase: 5 mg
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,879 Previous Clinical Trials
41,013,204 Total Patients Enrolled
1,402 Trials studying Lymphoma
382,835 Patients Enrolled for Lymphoma
Fox Chase Cancer CenterLead Sponsor
233 Previous Clinical Trials
38,828 Total Patients Enrolled
14 Trials studying Lymphoma
143 Patients Enrolled for Lymphoma
National Institutes of Health (NIH)NIH
2,798 Previous Clinical Trials
8,141,483 Total Patients Enrolled
27 Trials studying Lymphoma
12,954 Patients Enrolled for Lymphoma
Share this study with friends
Copy Link
Messenger